Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Cibinqo
| Field | Information |
|---|---|
| Medication Name | Cibinqo |
| Generic Name | Abrocitinib |
| Boxed/Label Warning | Cibinqo is associated with an increased risk of serious infections, malignancy, and thrombosis. |
| Purpose | Treatment of moderate-to-severe atopic dermatitis (eczema) in adults and children 12 years and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when those therapies are not advisable. |
| Mechanism of Action | Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which are involved in inflammation and immune response. |
| Dosage Forms | Oral tablets |
| Available Strengths | 50 mg, 100 mg, 200 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Nausea, headache, acne, herpes simplex infections (cold sores), increased blood creatinine phosphokinase (CPK) |
| Serious Side Effects | Serious infections (e.g., pneumonia, cellulitis, herpes zoster), malignancy (lymphoma, non-melanoma skin cancer), thrombosis (deep vein thrombosis, pulmonary embolism), major adverse cardiovascular events (MACE), elevated cholesterol and triglycerides. |
| Drug Interactions | Strong CYP2C19 inhibitors or inducers, moderate to strong CYP3A4 inhibitors or inducers, certain immunosuppressants. |
| Important Notes | Patients should be evaluated for active and latent tuberculosis (TB) before starting Cibinqo. Monitor for signs and symptoms of infection during and after treatment. Avoid use with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants. |
| Storage | Store at room temperature, away from moisture and light. |
| Missed Dose | Take the missed dose as soon as you remember unless it is almost time for your next dose. Do not double the dose. |
| Alternatives | Dupilumab (Dupixent), Tralokinumab (Adbry), Upadacitinib (Rinvoq), Topical corticosteroids, Crisaborole (Eucrisa). |
Cibinqo Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Dupilumab (Dupixent) | IL-4 receptor alpha subunit antagonist | Biologic injection for moderate-to-severe atopic dermatitis. |
| Tralokinumab (Adbry) | IL-13 antagonist | Biologic injection for moderate-to-severe atopic dermatitis. |
| Upadacitinib (Rinvoq) | JAK inhibitor | Oral medication for moderate-to-severe atopic dermatitis. |
| Topical corticosteroids | Anti-inflammatory | Applied directly to the skin to reduce inflammation and itching. |
Cibinqo Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Nausea | Serious infections (pneumonia, cellulitis, herpes zoster) |
| Headache | Malignancy (lymphoma, non-melanoma skin cancer) |
| Acne | Thrombosis (deep vein thrombosis, pulmonary embolism) |
| Herpes simplex infections (cold sores) | Major adverse cardiovascular events (MACE) |
| Increased blood CPK | Elevated cholesterol and triglycerides |
Cibinqo Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Atopic Dermatitis (Adults) | 100 mg or 200 mg once daily | May be reduced to 100 mg once daily based on response | Swallow tablet whole with or without food. |
| Atopic Dermatitis (Adolescents 12+ years) | 100 mg once daily | May be reduced to 50 mg once daily based on response | Swallow tablet whole with or without food. |
Cibinqo Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $50 – $400 |
| Without Insurance (U.S.) | $3,500 – $4,200 |
| From Canada | $2,299.50 |
